Fig. 1

Stress Levels and Formulation Process Pathway for Physicians Offering Long-Acting Injectable Antipsychotics. a Physicians’ stress levels when offering LAI over oral treatment - proportions of physicians who rated their level of stress as felt when offering LAI over oral antipsychotic formulations to patients with schizophrenia are shown. b Formulation process pathway: prescription of LAI vs oral treatment - proportions of patients that physicians declared for each stage of the formulation process pathway when prescribing a new antipsychotic and considering oral versus LAI antipsychotic formulations. Mean ± 95% CI is shown. c Formulation process pathway by stress level - the influence of stress associated with offering LAI compared to oral treatments on proportions of patients that physicians declared for each stage of the formulation process pathway. Mean ± 95% CI is shown. CI, confidence interval; LAI, long-acting injectable